BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not...


Sensys developed a non-invasive blood glucose monitor that used near infrared diffuse reflectance spectroscopy. The technology was designed to provide a painless method to collect data for proactive use in controlling diabetes.
Sensys Medical
Chandler, AZ